Immune-deficient patients depend on the antibodies in pooled human immunoglobulin G (IgG) preparations to remain free from serious infections. The potency of IgG preparations is therefore an ongoing concern. The use of pooled IgG to prevent infection is based on the concept that healthy adults have recovered from infections earlier in life and maintain relatively high antibody titers. In general, vaccine-induced immunity is less robust or longlasting than immunity after natural infection, and many infectious diseases which were formerly widely prevalent have become much less common due to improved hygiene and vaccines. This raises questions as to the adequacy of protective antibodies in current IgG preparations. This paper reviews available data on antibodies against selected bacterial and virus vaccine antigens in current IgG products. Most products contain sufficient antibody to yield levels above minimal protective concentrations to a broad range of pathogens and toxins. Illustrative examples of effects of vaccines on antibody content of IgG products are also discussed: antibody titers to hepatitis A virus in donor plasma pools in both the US and EU are dropping due to decreased natural infection, but they are still sufficient to provide robust protection. Increasing seroprevalence of hepatitis B virus as a result of immunization suggests that antibody titers against this virus may actually be increasing. Finally, serial studies suggest that pooled IgG provides protection against seasonal influenza viruses despite year-to-year antigenic drift, and is also likely to provide at least some protective antibody against potentially pandemic strains. P atients with primary immune deficiency diseases (PIDD) and other forms of humoral immune deficiency are dependent on the antibodies in pooled human immunoglobulin G (IgG) preparations to remain free from serious bacterial and viral infections. The US FDA has concluded that "available data do not permit identification of a trough (pre-next-dose) total …or pathogen-specific plasma IgG level which, if achieved and maintained, would ensure optimal protection from the risk of serious bacterial infection."
1 Therefore, we do not have standard requirements for antibody titers against most of the pathogens and toxins from which our patients need protection. Professional and patient organizations recommend that IgG replacement therapy regimens should be individualized according to each patient's clinical response. 2, 3 Analyses of relatively large pooled data sets show good correlations between increasing doses of both intravenous and subcutaneous IgG replacement therapy, the resulting rise in serum IgG levels and corresponding decreased rates of infection. 4, 5 In the 75 years since an IgG product was first licensed by the FDA, we have seen the introduction of many new vaccines with major impacts on the natural exposure to infectious agents. 6 
BINDING VS FUNCTIONAL ASSAYS AND PROTECTIVE VS NON-PROTECTIVE ANTIBODIES
Successful pathogens employ a wide variety of mechanisms to overcome or evade our mucosal and innate defenses and cause disease. "Virulence factors" that serve these functions include exo-and endotoxins, siderophores and other molecules responsible for metabolic adaptations, enzymes that degrade or defeat host defenses, and surface structures that allow the microbes to specifically adhere to or avoid certain types of cells. 10, 11 It is no surprise, therefore, that antibodies and other adaptive immune mechanisms must aim at a wide variety of targets to prevent infections. In some cases, neutralization of mucosal attachment (i.e., by IgA) may be sufficient to protect the host from invasion. 12, 13 Many organisms, particularly viruses, must travel through the blood stream to reach the particular site or cell-type in which they can replicate. 13 Such organisms are often susceptible to circulating antibodies that block or inactivate the surface molecules they use to attach to and enter their target cells. Antibodies which cause agglutination and/or activate mechanisms such as complement, phagocytosis, and intracellular killing may also be effective during bacteremia or viremia. Yet other organisms secrete exotoxins which contribute to local invasiveness or the disease symptoms they produce in the host. Induction of neutralizing antibodies against exotoxins is a major mechanism of action of several of our oldest and most reliable vaccines, such as diphtheria, tetanus, and pertussis toxoids. Micro-organisms are complex structures with multiple different antigens, which may be exposed vs. concealed on their surfaces. Even toxins have multiple epitopes which may or may not be involved in cell-binding or pathogenesis. Antibodies against different structures and epitopes may thus range from being potently protective to ineffectual, or may even enhance infection. Furthermore, antibodies themselves belong to different classes and subclasses, which are important determinants of their function in the host and their possible protective effects. It should thus be clear that the presence of antibodies that bind to an organism or toxin does not guarantee protection.
14 Prime examples of this are antibodies against the cell walls of encapsulated bacteria such as Streptococcus pneumoniae, which bind, but fail to promote phagocytosis because the over-lying capsule blocks their interactions with phagocytes. 15 Specific antibodies against exposed capsular polysaccharide antigens per se are necessary for opsonophagocytic killing and protection. 15 Similarly, antibodies against epitopes on viral surfaces may bind to molecules or epitopes other than those the virus uses to attach to and enter its target cells. 16 This is illustrated by HIV and the difficulties in producing an effective vaccine against it. 17, 18 Another important example is provided by comparing binding vs neutralizing antibody responses to a formalininactivated respiratory syncytial virus (RSV) vaccine which was evaluated in infants and young children in the 1960s. 19 The vaccine stimulated high rates of seroconversion and moderately high antibody titers as measured in complement fixation assays, but failed to induce resistance to infection. 19 Furthermore, when subsequently infected in the community, many vaccine recipients developed more serious lower respiratory tract disease than non-vaccinated individuals. 19 A study which compared ELISA titers of antibodies binding to the major RSV glycoproteins (F and G) to the neutralizing titers in a plaque reduction assay using a human epithelial tissue culture cell line (HEp-2) showed that the ratios of binding to neutralizing titers in vaccinated infants (2--7 months of age) and older children (7-40 months) were 250 and 650, respectively, while the ratios following natural infection in unvaccinated infants and children were 12.5 and 25, respectively. 20 It was concluded that the formalin treatment altered the epitopes of the viral antigens such that they elicited antibody responses with good binding but poor neutralizing activity. 20 A similar phenomenon may have occurred with a more recent dengue virus vaccine, which resulted in 95% seroconversion but only 30% efficacy. 21 In general, binding assays in which killed organisms or isolated antigen(s) are immobilized on a solid phase such as a plastic enzyme-linked immunoadsorbent assay (ELISA) plate or a visible or fluorescent microparticle are generally more rapid, more reproducible and easier to standardize than are assays of biological functions such as neutralization (prevention of infection of cells in vitro) or opsonophagocytic killing. 22, 23 Functional assays require viable target cells and/or phagocytes, which may be difficult to maintain and which are much more variable than isolated antigen molecules. 22, 24 A priori, we expect that neutralization or killing assays will correlate well with protection against infection 25 and therefore are likely to be more informative than binding assays, which might be measuring antibodies against irrelevant antigens. In fact, however, all laboratory assays are model systems which are merely surrogates for protection. Ultimately, therefore, the value of any given assay in assessing "protection" must be correlated with clinical studies which confirm that the result actually does correlate with protection against infection in vivo. 23, 25 Controlled vaccine trials followed by natural infection and/or clinical studies of the incidence of infection in individuals for whom pre-infection serum samples are available and subsequent exposure was similar are the major ways in which the "minimal protective antibody titer" is determined. 26, 27 However, even "protection" defined in this way may not always be the same in different populations or with different routes of exposure.
ANTIBODIES AGAINST COMMON BACTERIAL PATHOGENS AND TOXINS
Data allowing comparisons between antibacterial antibody titers in immunoglobulin preparations produced by different companies would be ideally obtained using standardized assays of biological function in a central laboratory. In part because documentation of potency of IgG preparations in the US is required only for measles virus, poliovirus, and diphtheria antibodies, published data on antibodies against other organisms is scant. This review focuses on studies from which μg of specific antibody per mg of total IgG or IU per mg total IgG could be calculated, so results can be compared across laboratories. Studies reporting titers from proprietary assays used only in individual laboratories are difficult to compare and have not been included. Current immunization schedules include 12 vaccines, many of which contain antigens against multiple different viruses or serotypes of bacteria, 28 40 There is good agreement on the content of antibodies against the Hemophilus influenzae type B polysaccharide between these three studies and across the multiple lots and products in the individual studies. There is also good agreement between the Matejschuk and Lejtenyi-Mazer studies for antibodies against those serotypes of Streptococcus pneumoniae which were reported from both studies. 39, 40 However titers for serotypes 4, 6B and 9 V reported by Mikolajczyk are somewhat lower than in the other two reports. 38 The studies of Matejschuk and Lejtenyi were published in 2002 and 2008 respectively, while the Mikolajczyk study was published in 2004, so it is not likely that changes in immunization status of the donor pool contribute to these differences. Within the Mikolaczyk study, the 2 products which had the highest titers against types 14 and 19F pneumococcus, also had high titers against H. influenzae. Results of opsonophagocytic activity (not shown in Table 1 ) were more dispersed, especially for type 6B S. Pneumoniae, in which two of the products differed from each other by more than 5 two-fold dilutions (1:64 vs. > 1:1024) (not shown). 38 Interestingly, the rank-orders of the different products against the different polysaccharides in the ELISA assays did not agree with their rank orders in the opsonophagocytic assays. 38 Mikolaczyk et al. subsequently fractionated the products into IgG subclasses. The majority of anti-polysaccharide antibodies as detected by both the ELISA and opsonophagocytosis assays were of the IgG 2 subclass. 38 With type 6B
pneumococcus, however, subclass 3 antibodies performed best in the opsonophagocytic assay. Of note, the opsonophagocytic assays were done in the absence of serum, so complement-activating properties of the different subclasses did not play a role. Calculations of expected trough serum IgG levels in PIDD patients receiving a replacement dose of 400 mg/kg/month suggested that all of the products would yield protective titers against all of the serotypes tested, with the possible exception of S. pneumoniae type 4. The manufacturing process used in the early 2000s for 4 of the products included solvent-detergent treatment, one included trypsin treatment and one, pepsin. The authors commented that since both the production methods and the immunization status of the donor pool change over time, it might prove useful to periodically reassess the antibacterial activities of the available products, 38 but it is not evident from published literature that this is occurring. In separate studies, Lee et al. examined specific antibodies against H.influenzae polysaccharides in multiple lots of two Korean products. 41 The mean contents of specific antibodies against H. influenzae polyribosyl-phosphate, 0.29 and 0.27 μg/mg total IgG for the different products, are in good agreement with the data for Western products. Assuming a dose of 400 mg IgG/kg in PIDD patients, calculations in the paper estimate that trough serum levels with all lots of both products would exceed the minimal protective level of 0.15 μg/ml.
41
Interestingly, pooled analyses of multiple IgG licensing studies estimated that the trough serum IgG levels in PIDD patients on intravenous IgG (IVIG) replacement therapy (n = 676) increase by 121 mg/dL for every 100 mg/kg/ month increase in dose, 4 and the steady state IgG levels rise by 84.4 mg/dL for every 100 mg/kg/month increase in dose of subcutaneous IgG (n = 482). 5 Thus, if specific antibody titers in the products are expressed as μg/mg total IgG, it is possible to easily calculate what dose is necessary to reach a given protective level in the patient's blood. Adam and Church studied peak and trough levels of antibodies against meningococcal serotypes A, C, W-135 and Y in PIDD patients on intravenous or subcutaneous IgG replacement therapy with a variety of IgG preparations at doses of ≥500 mg/kg/month. 36 These data on patient sera are not included in the tables, which list antibody content in IgG products only. Twenty-eight of 30 patients had at least some measurable antibody against all of serotypes tested. The titers against serogroups C and W-135 were somewhat lower than those against A and Y. Only a quarter of individuals had levels ≥ 2 μg/mL against serogroup C and only 10% had ≥ 2 μg/mL against serogroup W-135 at trough or steady state sampling. This is potentially concerning because serogroups C and B are the main causes of meningococcal outbreaks in the US. Lee et al. also measured complement-dependent serum bactericidal activity against the same 4 meningococcal serotypes. 41 For all serotypes, the geometric mean titers with both products fell within a two-fold range of each other. The highest titers in both products were against type W-135. The second highest titers were against type Y in one product and type A in the other; while type C had the lowest titers in both products. For both products, the calculated trough serum levels of antibodies against all 4 serotypes resulting from a dose of 400 mg/kg were estimated to exceed a "minimal protective value," except for 2/6 lots of one product. 41 It thus seems fair to conclude that virtually all IgG products contain satisfactory amounts of antibodies against most bacterial antigens in common vaccines, and that lotto-lot variation should not be a concern in practice. One exception to this conclusion might be N. meningitis type C, so if an outbreak of that is suspected, increased or extra doses of IgG replacement therapy might be prudent for PIDD patients at high risk of exposure.
Data on antibodies against measles virus, varicellazoster and rubella viruses in products produced from US, UK, and EU are also available in the studies by Wu, et al., 42 Matejtschuk, et al., 39 and Nobre et al., 43 and are summarized in Table 2 . The data across all three studies are in good agreement, and suggest that protective levels would be achieved in patients receiving these products.
ANTIBODIES AGAINST HEPATITIS A VIRUS AND HEPATITIS B VIRUS
The incidence and prevalence of both hepatitis A-and hepatitis B-virus (HAV, HBV) infections have decreased in most countries because of improvements in socioeconomic status and sanitation, but also because of development and use of effective vaccines. 44 Nevertheless, patients who cannot (Table 3) . Actual determinations of trough antibody levels in PIDD patients or calculations suggest that all of these would result in protective levels. Results for Japanese and Korean products from Lee et al. seem below this range, particularly for HBV. 45 The discrepancies between that study and the earlier studies may be due to technical differences in the way the assays were performed, differences in immunization practices in different countries, or other factors, and should be studied further. In studies in which results from multiple lots of the same product were reported, the coefficients of variation amongst the lots are generally within 25%. 39, 45 Antibody to HBV surface antigen (HBsAg) titers in the different studies also generally fall with a two-fold range, centered just under 2 IU/mL. 39, 45, 46 (Table 3 ) Data from PIDD patients receiving different IgG preparations at doses of 400 mg/kg every 3-4 weeks suggests that most patients maintain antiHBsAg titers above protective levels of 100 IU/L throughout their dosing intervals. 47 HAV provides an interesting example of the relationship between decreasing incidence of natural infection over time, decreasing antibody titers in the donor population, and decreasing titers in IgG products. This has been studied in detail by Farcet et al. and is illustrated by Fig 1. 46 As shown in panel A, anti-HAV titers in US plasma pools are consistently and significantly lower than EU pools. In both regions, the mean titers dropped in parallel between 2003 and 2008. As shown in panel B, neutralizing anti-HAV titers in final containers of a single IgG product show a similar and highly significant (p < 0.0001) difference depending on whether the product was made from plasma from EU (left) vs US plasma (right). 46 Despite the data showing that IgG derived from US plasma has only half as much neutralizing antibody as EU-derived IgG, even the titer in the US product, 14.6 IU/mL, is > 1000 fold higher than that needed to provide a minimal protective level of 10 mIU/ml in recipients' plasma. 45, 46 It is tempting to speculate that the situation with HBV might be opposite that for HAV, because the incidence of natural HBV infection amongst normal individuals is quite low but the availability and widespread use of an effective vaccine should have raised the seroprevalence amongst the potential donor population. Surveys of US military recruits reported a HBsAg seropositivity rate of 0.3% in 1992, compared to a positivity rate for anti-HBsAg of 31.5% in 2005. 48, 49 Plasma derived HBV vaccines were introduced in 1981 and the first recombinant HBsAg vaccine was licensed in the US in 1989. 6 However this change is believed to be mainly due to adherence to advisory committee on immunization practices recommendations in 1995 and 1997 for "catch-up" immunization of all unimmunized individuals < 18 years of age. 49 Comparative data on actual anti-HBsAg titers in IgG preparations before and after widespread immunization are not readily available, but titers would be expected to increase as the seroprevalence in the donor pool increases. Thus, while in general we are concerned about antibody titers declining as we switch from natural infection to vaccine-induced immunity, we may see the opposite trend as vaccines are introduced against relatively rarer infections. Data on antibody titers against human papilloma virures before vs after the relatively recent introduction of vaccines against that family could not be identified in published literature. A detailed analysis of antibodies in HBV hyperimmune globulin preparations 50 produced from plasma collected after vs before the current vaccines came into use is beyond the scope of this review.
ANTIBODIES TO INFLUENZA VIRUSES
Advising PIDD patients about whether their IgG replacement therapy protects them against influenza infection raises interesting questions. Patients may reasonably ask: "If the process of collecting, purifying, and distributing IgG takes a year or more from vein to vein, and if we are supposed to get a new flu vaccine every fall, then how am I protected against this year's flu by plasma from donors who received last year's vaccine?" Fortunately, immunizing close contacts with the current vaccine will likely reduce the patient's exposure, and we now have antiviral therapies in our armamentarium, but what do we know about crossprotection from year to year? Random mutations in the genes for the neuraminidase and hemagglutinins of Types A and B influenza viruses occur continually over time as the viruses replicate, and accumulate over time. These genetic changes are manifest immunologically as "antigenic drift" which is usually of a sufficient magnitude to require different vaccines to ensure robust protection every year, 51 although there may be crossprotection from recent years' vaccines or natural infection.
On the other hand, the more dramatic "antigenic shift" is an abrupt, major change in influenza A viruses, resulting in dramatically different hemagglutinin and/or neuraminidase proteins. 51 In contrast to the continuous process of antigenic drift, shift occurs only in type A viruses, and only occasionally. Antigenic shifts are thought to occur in animal populations such as birds and pigs, which can simultaneously harbor multiple types of viruses, such as swine, avian, and human. Reassortment of gene segments may result in emergence of viruses that are so different that most people lack immunity to the new (e.g., novel) virus. Such a "shift" occurred in the spring of 2009, when an H1N1 virus with a new combination of antigens emerged and spread quickly, causing a pandemic. 54 As with the Japanese study, the HI titers against the swine-origin 2009 virus were much lower than the titers against an earlier seasonal H1N1 isolate. 53, 54 Interestingly, the IgG preparations had no detectable HI activity against an H5N1 virus, but did provide protection against infection with that virus (Fig. 3B) , apparently due to crossreactivity with the neuraminidase. 52 This points out another way in which functional assays can differ from "antibody titers," and again illustrates their advantage over binding assays. Onodera et al. studied HI and neutralizing titers against seasonal and pandemic viruses in multiple lots of several IgG products made at different facilities in Japan from plasma collected in different years. 55 All of the IgGs had some activity against all of the viruses tested, with relatively little variation between consecutive lots, but slowly increasing titers over a 5-year period against strains which varied with seasonal drift. They found that the IgG preparations made from plasma collected before a given virus emerged also contained antibody against the newer viruses to which the donors had never been exposed. Thus, they concluded that the donor population and the IgG products maintain both specific and cross-reactive antibodies against seasonal viruses. So, we can answer the patients' question: if we see the usual antigenic drift, you would likely be protected by IgG made from plasma collected the previous year. Even if there is a major antigenic shift, IgG might still offer some protection because of cross-reactive antibodies, although higher doses might be required.
CONCLUSIONS
A periodically updated compendium of results of standardized functional assays for a wide variety of antibodies against important pathogens would be a great boon to patients, physicians, and regulators who are concerned with the potency of IgG products. However, documentation of potency is required as a lot-release criterion in the US only for measles and polio viruses and diphtheria toxin, and such a compendium does not exist. Data which are available for antibodies against common vaccine antigens suggest that most products contain sufficient antibody to result in titers above minimal protective levels in patients taking doses of IgG in the range of 400 mg/kg/month or higher. The data also suggest that lot-to-lot variation is within the range of AE25-30% of the mean for most antibodies, suggesting that selecting specific lots is not necessary to maintain protection. A variety of factors is contributing to decreases in the incidence of natural infection with many pathogens, including the introduction of new vaccines and changes in immunization schedules, as well as changes in hygiene. This results in changes in the antibody content of donor plasma pools, but titers against only a few antigens have been tracked. Antibody to HAV in plasma pools is dropping, but there are still sufficient antibodies in final products to provide robust protection. Increasing seroprevalence of HBV as a result of immunization suggests that antibody titers against this virus may actually be increasing. Finally, serial studies suggest that the donor pool and products contain both specific and broadly cross-reactive antibodies against seasonal influenza strains which differ by continuous antigenic drift, and there is likely at least some protective antibody against potentially pandemic strains which emerge due to reassortment and antigenic shift.
